Contract Deobligations Alert — July 24, 2026

Leidos Holdings subsidiary won a cost-plus-fixed-fee delivery order from NIH National Cancer Institute for Phase 1/2 vaccine trials through May 2029, with $36.8M already funded. Cost-plus structure minimizes profit risk and provides stable long-term revenue visibility.

Frequentis USA won a time-and-materials delivery order for APC units and APCMS through 2027, with $105.1M already outlayed. High funding certainty but limited margin upside due to contract type.

Raytheon (RTX) received a non-competed cost-plus-fixed-fee delivery order for aircraft ground handling equipment modification. While sole-source signals a strong incumbent position, the $28.3M annual revenue is immaterial for RTX ($69B+ revenue) and cost-plus limits margin upside.

PTSI Managed Services' $130.8M NASA contract is now complete (78% outlayed), creating a revenue gap risk if no follow-on awards are secured at Goddard Space Flight Center.

Frequentis USA is foreign-owned but U.S.-incorporated, exposing the $124.6M FAA contract to potential regulatory changes affecting foreign-owned defense/transportation contractors.

PTSI's $130.8M NASA contract was firm-fixed-price, transferring cost risk to the contractor. While apparently successful, any future similar awards carry execution risk on fixed-price elements.

Leidos' $173.3M NIH vaccine trial contract positions the company for follow-on awards if Phase 1/2 trials succeed, potentially expanding into larger Phase 3 contracts or production agreements.

Raytheon's sole-source $113.2M FAA STARS program award indicates an entrenched relationship that could yield additional non-competed task orders for air traffic control modernization.

Frequentis USA's $124.6M FAA delivery order for APC units suggests sustained investment in air traffic control telecom infrastructure, potentially leading to follow-on contracts beyond 2027.

All four contracts are civilian (HHS, NASA, DOT/FAA), totaling $541.8M, with no defense exposure. The mix of health R&D (Leidos), facility construction (PTSI), and air traffic equipment (Frequentis, Raytheon) indicates broad-based, non-cyclical civilian spending.

Leidos' $173.3M NIH contract and Raytheon's $113.2M FAA contract are both cost-plus-fixed-fee, reducing profit risk for complex R&D and engineering. Conversely, PTSI's $130.8M NASA contract is firm-fixed-price, transferring cost risk for construction.

{"entity" => "Leidos Holdings Inc. (LDOS)", "reason" => "$173.3M NIH vaccine trial contract provides long-term revenue visibility through 2029; successful trial outcomes could lead to expanded contracts.", "trigger" => "Announcements of successful vaccine trial outcomes or follow-on NIH awards"}

{"entity" => "Frequentis USA, Inc.", "reason" => "$124.6M FAA delivery order with $105.1M already outlayed; foreign ownership creates regulatory risk.", "trigger" => "Regulatory changes affecting foreign-owned contractors or FAA budget allocations for telecom equipment"}

{"entity" => "PTSI Managed Services Inc", "reason" => "$130.8M NASA contract now complete; revenue gap risk if no follow-on awards are secured.", "trigger" => "New NASA GSFC facility contracts awarded to PTSI or competitors"}